Research programme: anticancer antibody therapeutics - Adimab/Merrimack Pharmaceuticals

Drug Profile

Research programme: anticancer antibody therapeutics - Adimab/Merrimack Pharmaceuticals

Alternative Names: MM-131; Signaling inhibitors

Latest Information Update: 12 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adimab
  • Developer Adimab; Merrimack Pharmaceuticals
  • Class Antibodies; Bispecific antibodies
  • Mechanism of Action Epithelial cell adhesion molecule inhibitors; Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 08 Jan 2017 Research programme: anticancer antibody therapeutics - Adimab/Merrimack Pharmaceuticals is available for licensing as of 08 Jan 2017. www.merrimack.com
  • 10 Dec 2014 Preclinical development is ongoing USA
  • 19 Nov 2012 Preclinical development is ongoing USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top